(1) Criteria for determining the efficacy of malignant lymphoma 1. Complete remission (CR): the tumor disappears completely for more than one month. 2.Partial remission (PR): The product of the two largest diameters of the tumor is reduced by more than 50%, and other lesions do not increase in size, and it is maintained for more than one month. 3.No change (NC): The product of the two largest diameters of the tumor is reduced by less than 50%, or there is no significant change in size. 4.Deterioration (PD): tumor enlarges more than 25% or new metastases appear. (The recent remission rate of HD is higher than that of NHL, and the recent remission rate of HD in stage I-II is more than 95%; NHL can also achieve about 80% of recent remission after detailed examination and staging, careful staging and selection of appropriate treatment plan. (C) Long-term efficacy of malignant lymphoma The 5-year survival rate of patients with stage I-II HD has reached more than 95%, and the 5-year survival rate of patients with stage III-IV HD can also reach about 90%; although the treatment of more advanced cases of NHI is more difficult, its 5-year survival rate has also reached 80%. Therefore, for early lymphocyte-dominant and nodular sclerosis type HD, low malignancy NHL should strive to cure these cases. For more advanced malignant lymphoma with higher malignancy, we should strive to improve the 5-year survival rate. (D) Factors affecting prognosis 1. Age: Patients with Hodgkin’s disease have a higher survival rate at less than 50 years of age than at more than 50 years of age, and the prognosis of children and elderly patients with non-Hodgkin’s lymphoma is generally worse than those aged 20 to 50 years. 2. Gender: In patients with Hodgkin’s disease, women have a higher survival rate after treatment, while in non-Hodgkin’s lymphoma, there is little difference in prognosis between men and women. 3. Pathology: Among patients with Hodgkin’s disease, lymphocyte-dominant type has the best prognosis, with a 5-year survival rate of 94.3%, while nodular sclerosis and mixed cell type have the second best prognosis, and lymphocyte-cutting type has the worst prognosis, with a 5-year survival rate of only 27.4%. Among non-Hodgkin’s lymphoma, follicular lymphocyte differentiation is good, with a 6-year survival rate of 61%; diffuse lymphocyte differentiation is poor, with a 6-year survival rate of 42%; lymphoblastoid lymphoma, with a 4-year survival rate of 30%. 4.Stage: In patients with Hodgkin’s disease, the 5-year survival rate is 92.5% for stage I, 86.3% for stage II, 69.5% for stage III, and 31.9% for EF stage. 5. Systemic symptoms: The prognosis of Hodgkin’s disease patients with systemic symptoms is worse than that of those without systemic symptoms, while for non-Hodgkin’s lymphoma, systemic symptoms have less impact on prognosis.